49 completed. 49 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 49 | Completed 49 |
| Phase 2 | 6 | Completed 6 |
Follow Contraception: new trials by email Literature Review of Contraception trials Research Report on Contraception
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring EVE119 vaginal ring, Nuvaring vaginal ring - Healthy Women, Female | Phase 1 | Completed | Evestra Inc. | 36 | 2023-07-29 | 2024-06-24 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects LINO-1713 1 tablet, LINO-1713 once a day for 24 days - Contraception | Phase 1 | Completed | Hyundai Pharm | 20 | 2022-01-11 | 2023-01-11 |
| A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age TV-46046, Depo-subQ Provera - Contraception | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 60 | 2020-12-14 | 2024-02-26 |
| The Effects of Annovera™ and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol Segesterone Acetate and Ethinyl Estradiol, Tampon - Contraception | Phase 1 | Completed | TherapeuticsMD | 21 | 2020-03-06 | 2021-10-29 |
| Annovera™ Drug-Drug Interaction Study Segesterone Acetate and Ethinyl Estradiol, Rifampin, Itraconazole - Women, Contraception | Phase 1 | Completed | TherapeuticsMD | 67 | 2020-02-12 | 2021-01-29 |
| A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046 TV-46046, Depo-subQ 104, TV-46046 Placebo - Contraception | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 27 | 2019-01-15 | 2022-01-26 |
| PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel VR: 200 mg DPV + 320 mg LNG - Healthy, Contraception | Phase 1 | Completed | International Partnership for Microbicides, Inc. | 25 | 2018-07-17 | 2019-10-09 |
| Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study E4/DRSP, VAL - Contraception | Phase 1 | Completed | Estetra | 24 | 2018-04-12 | 2018-12-14 |
| On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility Ulipristal Acetate 30 MG Oral Tablet - Contraception | Phase 1 | Completed | Stanford University | 12 | 2018-03-15 | 2019-06-25 |
| The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users Topiramate - Migraine, Migraine;Menstrual | Phase 1 | Completed | University of Colorado, Denver | 48 | 2018-03-15 | 2022-07-13 |
| Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate Test formulation, Reference formulation - Contraception | Phase 1 | Completed | Galeno Desenvolvimento de Pesquisas Clínicas | 24 | 2017-03-31 | 2018-02-23 |
| Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers 5 mg E4 single-dose, 15 mg E4 single-dose, 45 mg E4 single-dose - Contraception, Menopause | Phase 1 | Completed | Estetra | 31 | 2017-01-31 | 2017-09-08 |
| Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation Ulipristal Acetate, Combined Oral Contraceptive Pill - Contraception | Phase 1 | Completed | Columbia University | 29 | 2016-12-16 | 2020-02-07 |
| Lower Dose Depo Provera® Contraceptive Injection Depo-Provera CI, Depo-subQ 104 - Contraception | Phase 1 | Completed | FHI 360 | 60 | 2016-12-02 | 2018-06-14 |
| Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle TV-46046 - 400 mg/mL, TV-46046 - 200 mg/mL - Pregnancy, Contraception | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 12 | 2016-10-26 | 2024-02-12 |
| "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" 15 mg E4/3 mg DRSP, 30 mcg EE/150 mcg LNG, 20 mcg EE/3 mg DRSP - Contraception, Liver Metabolism | Phase 1 / Phase 2 | Completed | Estetra | 101 | 2016-09-01 | 2018-02-05 |
| E4/DRSP Single and Multiple Dose PK and Early QT Study 15 mg E4/3 mg DRSP, 30 mg E4/6 mg DRSP, 60 mg E4/12 mg DRSP - Contraception | Phase 1 | Completed | Estetra | 55 | 2016-05-01 | 2017-04-21 |
| Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol Estetrol - Contraception, Menopause | Phase 1 | Completed | Estetra | 6 | 2016-02-01 | 2019-02-15 |
| Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods DMPA 150, DMPA 300, DMPA 104 - Contraception | Phase 1 | Completed | FHI 360 | 42 | 2015-09-01 | 2018-10-18 |
| Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female Volunteers 15 mg E4/3 mg DRSP - Contraception | Phase 1 | Completed | Estetra | 28 | 2015-08-01 | 2016-08-02 |
Showing 20 of 49. Sign in to see all of them.
Hypogonadism (2) · Breast Neoplasms (1) · Contraception Behavior (1) · HIV Infections (1) · Migraine Disorders (1)
Endocrine System Diseases (2) · Gonadal Disorders (2) · Behavior (1) · Blood-Borne Infections (1) · Brain Diseases (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Communicable Diseases (1) · Genital Diseases (1) · Headache Disorders (1) · Headache Disorders, Primary (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Lentivirus Infections (1)
Medroxyprogesterone Acetate (6) · Testosterone (6) · acyline (5) · drospirenone (5) · Estetrol (4) · Ethinyl Estradiol (4) · Levonorgestrel (4) · levomefolate calcium (4) · Folic Acid (3) · drospirenone and ethinyl estradiol combination (3) · Meloxicam (2) · N,N-dimethyl-4-anisidine (2) · norelgestromin (2) · norgestimate (2) · segesterone acetate and ethinyl estradiol vaginal system (2)
Bayer (8) · University of Washington (7) · Estetra (6) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (5) · CONRAD (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · FHI 360 (2) · Premier Research (2) · TherapeuticsMD (2) · University of Colorado, Denver (2) · Columbia University (1) · Evestra Inc. (1) · Galeno Desenvolvimento de Pesquisas Clínicas (1) · Hyundai Pharm (1) · International Partnership for Microbicides, Inc. (1)
United States (22) · Dominican Republic (6) · Germany (4) · Canada (3) · Netherlands (3) · Brazil (2) · Chile (2) · Mexico (2) · United Kingdom (2) · Bulgaria (1) · Finland (1) · South Korea (1) · Sweden (1)
Christina Wang, MD (2) · John K Amory (2) · Sebastian Mirkin, MD (2) · Vera Halpern, MD (2) · William J Bremner, MD, PhD (2) · Carolyn Westhoff, MD (1) · Chris Mauck, MD (1) · Christine Klipping (1) · Christine Mauck (1) · David F Archer, MD (1) · Dobrin Sviranov, MD (1)
PMID 17494097, PMID 20378927, PMID 16352669, PMID 16882745, PMID 16940442, PMID 17303493, PMID 17510436, PMID 18046048, PMID 19366848, PMID 22067789, PMID 22909145, PMID 23265980, PMID 23610531, PMID 24777591, PMID 29953547, PMID 31107913, PMID 31442441, PMID 33485608, PMID 35015210, PMID 35470225, PMID 35594123, PMID 37823034, PMID 39808648, PMID 41291952
2016 (3), U54HD042454 (3), 2005 (2), 2009 (2), K23HD045386 (2), 2014 (1), 2015 (1), 2017 (1), 5UM1AI068633 (1)